Table 3 Summary of reports of SGLT2 inhibitor use in diabetic renal transplant patients
Number of cases | Age (years), mean ± SD or (range) | Sex, male/female | eGFR (mL/min/1.73 m2); baseline changes after SGLT2 inhibitor | HbA1c (%); baseline changes after SGLT2 inhibitor | Systolic blood pressure (mmHg); baseline changes after SGLT2 inhibitor | Diastolic blood pressure (mmHg); baseline changes after SGLT2 inhibitor | Body weight (kg); baseline changes after SGLT2 inhibitor | References |
|---|---|---|---|---|---|---|---|---|
14 | 56.5 ± 7.9 | 7/7 | 54.0 ± 23.8; 53.5 ± 13.3 | 6.7 ± 0.7; 7.1 ± 0.8 | 150 ± 26; 145 ± 20 | 86 ± 14; 76 ± 11 | 83.7 ± 7.6; 78.7 ± 7.7 | [15] |
22 | 63 (31–72) | 17/5 | 66 (57–68); 59 (52–67) | 6.9 (6.5–8.2); 6.9 (6.4–7.4) | 143 (111–176); 140 (100–163) | 76 (71–82); 80 (74–86) | 92.0 (81.8–104.5); 85.0 (79.5–97.5) | [16] |
4 (SPKTR) | 49.4 ± 8.9 | 2/2 | 60 ± 14; a− 4.3 ± 12.2 | 7.4 ± 1.1; a− 0.84 ± 1.2 | Not provided; a− 6.5 ± 10.8 | Not provided; a− 4.8 ± 12 | Not provided; a− 2.14 ± 2.8 | [17] |
6 (KTR) | 61. ± 12.6 | 5/1 | 78 ± 18.2; a− 4.3 ± 12.2 | 8.6 ± 1.4; a− 0.84 | Not provided; a− 6.5 ± 10.8 | Not provided; a− 4.8 ± 12 | Not provided; a− 2.14 ± 2.8 | |
24 | 53.8 ± 7.1 | 23/1 | Ccr 86 ± 20; 83 ± 18 | 8.5 ± 1.5; 7.6 ± 1.0 | 142 ± 21; 134 ± 17 | 81 ± 9; 79 ± 8 | 78.6 ± 12.1; 76.2 ± 10.9 | [18] |
8 | 56.8 ± 13.7 | 6/2 | 75.75 ± 13.38; 69.88 ± 14.70 | 9.34 ± 1.36; 7.41 ± 1.44 | 135 ± 9.59; 126.43 ± 11.46 | 80.63 ± 10.13; 74.75 ± 7.25 | BMI 32.74 ± 7.2; 27.4 ± 4.2 | [19] |